Comparison of the efficacy and tolerability of tocilizumab, sarilumab, and sirukumab in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bae, Sang-Cheol | - |
dc.contributor.author | Lee, Young Ho | - |
dc.date.accessioned | 2021-09-02T11:15:59Z | - |
dc.date.available | 2021-09-02T11:15:59Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2018-06 | - |
dc.identifier.issn | 0770-3198 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/75427 | - |
dc.description.abstract | The relative efficacy and tolerability of tocilizumab, sarilumab, and sirukumab were assessed in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX) or tumor necrosis factor (TNF) inhibitors. We performed a Bayesian network meta-analysis to combine direct and indirect evidence from randomized controlled trials (RCTs) to examine the efficacy and safety of tocilizumab, sarilumab, and sirukumab in RA patients and an inadequate MTX or TNF inhibitor response. Fourteen RCTs, comprising 9753 patients, met the inclusion criteria. Tocilizumab 8 mg combined with MTX or as monotherapy was the most effective treatment for active RA with an inadequate MTX or TNF antagonist response, followed by sarilumab and sirukumab, regardless of MTX combination. The ranking probability based on the surface under the cumulative ranking curve (SUCRA) indicated that tocilizumab 8 mg + MTX had the highest probability of being the best treatment to achieve the ACR50 response rate, followed by tocilizumab 8 mg, sarilumab 200 mg, sarilumab 200 mg + MTX, sirukumab 100 mg, tocilizumab 4 mg + MTX, sirukumab 100 mg + MTX, sirukumab 50 mg + MTX, sarilumab 150 mg + MTX, adalimumab 40 mg, and sirukumab 50 mg, and placebo + MTX. No significant differences were observed in withdrawals owing to adverse events after treatment with tocilizumab 8 mg + MTX, sirukumab 100 mg + MTX, or sarilumab 200 mg + MTX. In RA patients with an inadequate MTX or anti-TNF therapy response, tocilizumab 8 mg as monotherapy and combined with MTX showed acceptable tolerability and the highest performance based on the ACR50 response rate, followed by sarilumab and sirukumab. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER LONDON LTD | - |
dc.subject | MODIFYING ANTIRHEUMATIC DRUGS | - |
dc.subject | INTERLEUKIN-6 RECEPTOR INHIBITION | - |
dc.subject | INADEQUATE RESPONSE | - |
dc.subject | DISEASE-ACTIVITY | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | CLINICAL-TRIALS | - |
dc.subject | METHOTREXATE | - |
dc.subject | MONOTHERAPY | - |
dc.subject | SAFETY | - |
dc.title | Comparison of the efficacy and tolerability of tocilizumab, sarilumab, and sirukumab in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Young Ho | - |
dc.identifier.doi | 10.1007/s10067-018-4006-5 | - |
dc.identifier.scopusid | 2-s2.0-85044587816 | - |
dc.identifier.wosid | 000431943200005 | - |
dc.identifier.bibliographicCitation | CLINICAL RHEUMATOLOGY, v.37, no.6, pp.1471 - 1479 | - |
dc.relation.isPartOf | CLINICAL RHEUMATOLOGY | - |
dc.citation.title | CLINICAL RHEUMATOLOGY | - |
dc.citation.volume | 37 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1471 | - |
dc.citation.endPage | 1479 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | MODIFYING ANTIRHEUMATIC DRUGS | - |
dc.subject.keywordPlus | INTERLEUKIN-6 RECEPTOR INHIBITION | - |
dc.subject.keywordPlus | INADEQUATE RESPONSE | - |
dc.subject.keywordPlus | DISEASE-ACTIVITY | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | CLINICAL-TRIALS | - |
dc.subject.keywordPlus | METHOTREXATE | - |
dc.subject.keywordPlus | MONOTHERAPY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordAuthor | IL-6, biologics | - |
dc.subject.keywordAuthor | Network meta-analysis | - |
dc.subject.keywordAuthor | Rheumatoid arthritis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.